<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="795">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <nctid>NCT00174837</nctid>
  <trial_identification>
    <studytitle>TRACE: Tirapazamine-Radiation And Cisplatin Evaluation</studytitle>
    <scientifictitle>Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer</scientifictitle>
    <utrn />
    <trialacronym>TRACE</trialacronym>
    <secondaryid>SR259075</secondaryid>
    <secondaryid>EFC5512</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Head and Neck Squamous Cell Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Head and neck</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Tirapazamine
Treatment: drugs - Cisplatin

Experimental: Tirapazamine + Cisplatin - 

Active Comparator: Cisplatin - 


Treatment: drugs: Tirapazamine
in combination with cisplatin and concomitant radiation

Treatment: drugs: Cisplatin
with concomitant radiation

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Study period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Failure Free Survival, Time To Loco-Regional Failure, Patterns of Failure</outcome>
      <timepoint>Study period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Initial Response Rates at 2 Months After Completion of Chemoradiation Therapy, Final complete response (CR) Rate at Six Months After Completion of Therapy</outcome>
      <timepoint>Study period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in QoL From Baseline, Percent of Patients Who Are Feeding Tube Dependent 12 Months After Completion of Therapy</outcome>
      <timepoint>Study period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity and Safety</outcome>
      <timepoint>Study period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Previously untreated squamous cell carcinoma of the oral cavity, oropharynx,
             hypopharynx, or larynx.

          -  Stage III or IV disease (excluding T1N1, and T2N1 and metastatic disease).

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.

          -  Absolute neutrophil count at least 1.5 X 10^9/L, platelet count at least 100 X 10^9/L,
             and hemoglobin &gt; 9g/dL.

          -  Serum bilirubin &lt; 1.25 times upper limit of normal (ULN) and aspartate
             aminotransferase (AST)/alanine transaminase (ALT) &lt; 2.5 times ULN.

          -  Calculated creatinine clearance (Cockcroft-Gault) &gt; 55 mL/min.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Metastatic Disease

          -  Primary cancers of the nasal and paranasal cavities and of the nasopharynx

          -  Significant intercurrent illness that will interfere with the Chemotherapy or
             Radiation Therapy during the trial

          -  Symptomatic peripheral neuropathy &gt; grade 2

          -  Clinically significant hearing impairment

          -  Significant cardiac disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>317</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sanofi-Aventis Administrative Office - Cove</hospital>
    <postcode> - Cove</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Laval</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Causeway Bay</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Macquarie Park</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Midrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Groupe Oncologie Radiotherapie Tete et Cou</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The trial will compare the efficacy and safety of concomitant chemoradiation with
      tirapazamine, cisplatin and radiation versus cisplatin and radiation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00174837</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ICD CSD</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>